Certified Nurse-Midwife Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kimberly Booker

Advanced Practice Midwife Reidsville, NC Certified Nurse-Midwife

NPI 1013359934 CMS profile 11082781

3871 Vance Street Ext, Reidsville, NC 27320

Open in the dashboard

General payments

$1,404

81 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kimberly Booker of Reidsville, NC is reported in the CMS Open Payments database as having received $1,404 across 81 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Advanced Practice Midwife profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $234 17
2024 General $171 10
2023 General $332 18
2022 General $320 18
2021 General $347 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kimberly Booker
  • Advanced Practice Midwife median
  • Middle half of Advanced Practice Midwife
  • National median

In program year 2025, general payments to Kimberly Booker were reported at $234. Among 4,127 Advanced Practice Midwife profiles paid that year, the median was $71 and the middle half received between $28 and $161.

Show as a table
Year Kimberly Booker Advanced Practice Midwife median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $347 $57 $22–$142 $132
2022 $320 $61 $23–$157 $149
2023 $332 $68 $26–$167 $160
2024 $171 $63 $25–$142 $164
2025 $234 $71 $28–$161 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $461 23 payments
  2. Mayne Pharma Inc. $238 17 payments
  3. Evofem Biosciences, Inc. $180 12 payments
  4. Pfizer Inc. $139 8 payments
  5. Exeltis, USA Inc. $136 7 payments
  6. TherapeuticsMD, Inc. $41 2 payments
  7. Sumitomo Pharma America, Inc. $37 2 payments
  8. ASCEND Therapeutics US, LLC $36 2 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $31 2 payments
  10. Hologic, LLC $22 1 payment
  11. Other $83 5 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,404 81 payments
Products named General payments · program years 2021–2025
  1. LO LOESTRIN FE $297 14 payments
  2. PREMARIN $166 10 payments
  3. LILETTA $145 8 payments
  4. MYFEMBREE Genitourinary (Sexual Health);Womens Health $126 7 payments
  5. ESTRING $118 7 payments
  6. ORILISSA $74 3 payments
  7. Phexxi $69 4 payments
  8. SLYND $67 3 payments
  9. DUAVEE $61 3 payments
  10. MYFEMBREE Hormone Therapy $57 3 payments
  11. Other $604 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

81 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record